Patent and Trademark Office

Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary

Retrieved on: 
Wednesday, August 14, 2019
Intellectual property law, Patent law, United States patent law, Patent and Trademark Office, Patent

SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it hasreceived a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application (U.S. Patent Application No.

Key Points: 
  • SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it hasreceived a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application (U.S. Patent Application No.
  • Adamis already has an issued United States Patent (U.S. 10,137,111) which recites compositions including omeprazole and fenbendazole.
  • The current allowance strengthens Adamis position in the equine treatment market.
  • Except to the extent required by law, Adamis expressly disclaims any obligation to update any forward-looking statements.

OncoSec Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Application with Claims Covering Cytokine-Based Intratumoral Immunotherapies

Retrieved on: 
Monday, July 29, 2019
Branches of biology, Biology, Virotherapy, Immunotherapy, Life sciences, Patent and Trademark Office, Electroporation

SAN DIEGO and PENNINGTON, N.J., July 29, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application 15/561,915.

Key Points: 
  • SAN DIEGO and PENNINGTON, N.J., July 29, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application 15/561,915.
  • "The claims granted by the USPTO provide OncoSec with broad-based protection on the very valuable combination of intratumoral cytokines, electroporation and checkpoint inhibitor therapy.
  • OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.
  • We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

SecuredTouch Granted Patent for Continuous User Authentication

Retrieved on: 
Monday, July 22, 2019
Cryptography, Intellectual property law, Computer access control, Surveillance, Access control, Authentication, Notary, Packaging, Strong customer authentication, Biometrics, United States Patent and Trademark Office, Patent and Trademark Office

TEL AVIV, Israel, July 22, 2019 /PRNewswire/ -- SecuredTouch, a leading provider of behavioral biometrics fraud detection solutions, announced today that the United States Patent & Trademark Office (USPTO), has granted the company a patent US 10366217, entitled "Continuous User Authentication".

Key Points: 
  • TEL AVIV, Israel, July 22, 2019 /PRNewswire/ -- SecuredTouch, a leading provider of behavioral biometrics fraud detection solutions, announced today that the United States Patent & Trademark Office (USPTO), has granted the company a patent US 10366217, entitled "Continuous User Authentication".
  • SecuredTouch Behavioral Biometrics technology learns and identifies patterns of human interactions with physical devices to identify the user, differentiate the human from the bot and set apart the device from an emulator.
  • "This patent places SecuredTouch at the forefront of innovation in user authentication.
  • The patent has been granted in proximity to the European Banking Authority (EBA) announcement that validates behavioral biometrics as an inherence element for Strong Customer Authentication (SCA) for PSD2 compliance.

Metaurus Advisors is Granted Patent for the First-Ever Splitting of an Equity Index into Separate Components of Dividends and Price

Retrieved on: 
Monday, July 15, 2019
Insurance, Finance, Consulting, Banking, Accounting, Professional services, Small business, Intellectual property law, Intellectual property organizations, Dividend, Shareholders, Metauro, Patent and Trademark Office

Metaurus Advisors , a financial innovation and asset management company, today announced it was granted a patent (USPTO Patent No.

Key Points: 
  • Metaurus Advisors , a financial innovation and asset management company, today announced it was granted a patent (USPTO Patent No.
  • View the full release here: https://www.businesswire.com/news/home/20190715005458/en/
    Metaurus Advisors is Granted Patent for the First-Ever Splitting of an Equity Index into Separate Components of Dividends and Price (Photo: Business Wire)
    We are very pleased that the US Patent and Trademark Office recognized Metaurus innovation.
  • The Metaurus Ex-Dividend Fund represents the Price Component, and is the remaining exposure to the S&P 500 Index after the future dividends have been stripped out.
  • For additional information on Metaurus, please visit www.metaurus.com | Twitter: @metaurusllc |LinkedIn: Metaurus Advisors LLC
    View source version on businesswire.com: https://www.businesswire.com/news/home/20190715005458/en/

Recros Medica Announces Patent for Autologous Dermal Transfer Issued by USPTO

Retrieved on: 
Tuesday, July 9, 2019
Intellectual property law, Plastic surgery, Injectable filler, United States Patent and Trademark Office, Patent and Trademark Office

SAN DIEGO, July 9, 2019 /PRNewswire/ -- Recros Medica, Inc. , today announcedthat the US Patent and Trademark Office (USPTO) has issued a new patent for a novel application to treat patients' aesthetic defects with their own skin.

Key Points: 
  • SAN DIEGO, July 9, 2019 /PRNewswire/ -- Recros Medica, Inc. , today announcedthat the US Patent and Trademark Office (USPTO) has issued a new patent for a novel application to treat patients' aesthetic defects with their own skin.
  • The company is also developing the RFR application to facilitate autologous dermal transfer as an alternative to commercial dermal fillers.
  • The patent was issued to SRGI Holdings, which has licensed all aesthetic uses to Recros Medica.
  • Autologous dermal transfer may allow physicians to provide aesthetic benefits to both the donor site and the target treatment site.

The U.S. Patent and Trademark Office and the National Crime Prevention Council collaborate to raise awareness about counterfeit goods

Retrieved on: 
Monday, July 1, 2019
Intellectual property law, United States Patent and Trademark Office, Counterfeit consumer goods, Trademark, Patent and Trademark Office, Counterfeit, United States trademark law

ALEXANDRIA, Va., July 1, 2019 /PRNewswire/ --The United States Patent and Trademark Office (USPTO) and the National Crime Prevention Council (NCPC) are collaborating to raise public awareness of the dangers related to and damage caused by purchasing counterfeit goods.

Key Points: 
  • ALEXANDRIA, Va., July 1, 2019 /PRNewswire/ --The United States Patent and Trademark Office (USPTO) and the National Crime Prevention Council (NCPC) are collaborating to raise public awareness of the dangers related to and damage caused by purchasing counterfeit goods.
  • The public may not know that counterfeit goods threaten consumers' health and safety, hurt the U.S. economy, and support international organized crime.
  • The United States Patent and Trademark Office (USPTO) is the federal agency for granting U.S. patents and registering trademarks.
  • The National Crime Prevention Council is the nonprofit leader in crime prevention.

CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation

Retrieved on: 
Wednesday, June 26, 2019
Intellectual property law, CytRx, United States Patent and Trademark Office, Patent and Trademark Office, OTC Markets Group

LOS ANGELES, June 26, 2019 /PRNewswire/ --CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the formulation, storage, delivery and administration of aldoxorubicin at room temperature.

Key Points: 
  • LOS ANGELES, June 26, 2019 /PRNewswire/ --CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the formulation, storage, delivery and administration of aldoxorubicin at room temperature.
  • Aldoxorubicin rights were exclusively licensed by CytRx to NantCell, Inc. in July 2017.
  • The new patent, which issued on June 25, 2019 as U.S. Patent No.
  • CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics to treat patients with high unmet needs.

Virgo receives first patent and celebrates 30,000th gastroenterology procedure recorded with cloud video platform

Retrieved on: 
Tuesday, May 14, 2019
Intellectual property law, United States Patent and Trademark Office, United States trademark law, Patent and Trademark Office

SAN FRANCISCO, May 14, 2019 /PRNewswire/ -- Virgo Surgical Video Solutions, Inc. , a San Francisco based digital health company, received its first patent and celebrated the 30,000th gastroenterology procedure recorded with the Virgo cloud video platform.

Key Points: 
  • SAN FRANCISCO, May 14, 2019 /PRNewswire/ -- Virgo Surgical Video Solutions, Inc. , a San Francisco based digital health company, received its first patent and celebrated the 30,000th gastroenterology procedure recorded with the Virgo cloud video platform.
  • Virgo's proprietary cloud video platform solves these challenges, creating a new best practice for endoscopic video recording.
  • The two-year-old company was recently granted its first patent by the United States Patent and Trademark Office (USPTO) for an Automated System for Medical Video Recording and Storage.
  • Earlier this month, the company celebrated the 30,000th gastroenterology procedure recorded on its cloud video platform.

IdentityMind Awarded New Patent on Using the Digital Identity Graph to Uncover Risk in Digital Transactions

Retrieved on: 
Tuesday, April 23, 2019
Computer access control, Digital identity, Digital technology, Federated identity, Identity, Identity management, Patent and Trademark Office, Logarithm, Information and communications technology, Abstraction, Logic

PALO ALTO, Calif., April 23, 2019 /PRNewswire-PRWeb/ -- IdentityMind, Digital Identities you Can Trust, announced today that the U.S. Patent and Trademark Office (USPTO) has granted IdentityMind a patent for utilizing features of its Identity Graph to yield a risk score -- "Graph Score" - to assess the risk of transactions performed by the digital identities represented in the graph.

Key Points: 
  • PALO ALTO, Calif., April 23, 2019 /PRNewswire-PRWeb/ -- IdentityMind, Digital Identities you Can Trust, announced today that the U.S. Patent and Trademark Office (USPTO) has granted IdentityMind a patent for utilizing features of its Identity Graph to yield a risk score -- "Graph Score" - to assess the risk of transactions performed by the digital identities represented in the graph.
  • IdentityMind's latest digital identity patent builds on the strength of IdentityMind's core Electronic DNA (eDNA) technology to further leverage digital identities to help protect financial transactions.
  • "The IdentityMind platform has been, from day one, built on digital identities," said Jose Caldera, IdentityMind's Chief Products and Marketing Officer.
  • "The combination of Graph Score and the eDNA reputation yields unprecedented accuracy in its assessment of the transaction risk associated with a specific digital identity.

US Patent & Trademark Office Issues Patent on Anixa Biosciences CAR-T Cancer Treatment Technology

Retrieved on: 
Wednesday, April 17, 2019
Intellectual property law, United States Patent and Trademark Office, United States trademark law, Patent and Trademark Office, Patent

SAN JOSE, Calif., April 17, 2019 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued US Patent No.

Key Points: 
  • SAN JOSE, Calif., April 17, 2019 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body's immune system to fight cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued US Patent No.
  • This is the first patent covering Anixa's CAR-T cancer treatment technology.
  • The patent is titled "METHODS AND COMPOSITIONS FOR TREATING CANCER," and the inventors are Drs.
  • The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc. is the exclusive, world-wide licensee.